Improving Radiation Therapy For Pancreatic Cancer
改善胰腺癌的放射治疗
基本信息
- 批准号:8880445
- 负责人:
- 金额:$ 18.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdenocarcinomaAdenocarcinoma CellAgreementAlcoholismAllogenicApoptosisAutologousBindingBiological ModelsBreast Cancer CellCell LineCellsClinicalComplexCopperCopper GluconateCytotoxic T-LymphocytesCytotoxic agentDiagnosisDiseaseDisulfiramDown-RegulationDuctalEarly DiagnosisEpitopesExcisionFDA approvedFaceFluorouracilFoundationsGenerationsGenesGoalsHelper-Inducer T-LymphocyteHumanImmunotherapyIn VitroIonizing radiationKnowledgeMAP Kinase GeneMalignant NeoplasmsMalignant neoplasm of pancreasMessenger RNAMethodologyModalityMusNeoadjuvant TherapyNeoplasm MetastasisOperative Surgical ProceduresOralOral AdministrationOxidation-ReductionPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlayProtein IsoformsRadiationRadiation therapyRadiation-Induced CancerRadiation-Sensitizing AgentsReactionReactive Oxygen SpeciesRecurrenceRegimenResectableResistanceRoleSignal TransductionSourceStagingSurvival RateT-LymphocyteTestingTherapeuticTimeToxic effectTrace ElementsTumorigenicityUp-Regulationalcoholism therapyaldehyde dehydrogenase 1aldehyde dehydrogenasesbasebeta catenincancer cellcancer stem cellcancer therapychemoradiationchemotherapyclinical applicationcomparative efficacydietary supplementsimprovedin vivoinhibitor/antagonistirradiationkillingsmouse modelneoplastic cellnovelnovel strategiesnovel therapeuticsnutritionoutcome forecastpancreatic cancer cellspancreatic neoplasmpreventpublic health relevanceradioresistantresponsestemstemnesstumor
项目摘要
DESCRIPTION (provided by applicant): Radiation therapy plays a key role in pancreatic ductal adenocarcinoma (PDAC) treatment. However, it faces challenges from the fact that pancreatic cancer stem cells (PCSC) are resistant to ionizing radiation. Moreover, a recent finding indicates that radiation can reprogram nonstem- cancer cells into cancer stem cells, which is in agreement with our finding, namely iPCSC. Compelling evidence show that PDAC cells in expressing elevated levels of aldehyde dehydrogenase 1 (ALDH1), ALDHbrightcells, are PCSC/iPCSC. In the past, we demonstrated that cytotoxic T cells (CTL) specifically recognizing an epitope from the ALDH1A1 isoform eliminate ALDHbright cells in vitro and in vivo. However, the clinical applicability of adoptive T cell-based immunotherapy is limited by HLA class I restriction and requires ex vivo expansion of autologous or allogeneic T cells using a variety of methodologies. To overcome the limitations of CTL-targeting of ALDHbright cells, we tested the novel approach of using disulfiram (DSF) to target PCSC. DSF is a dithiocarbamate and an FDA-approve inhibitor of ALDH for treatment of alcoholism. Its toxicity to PDAC cells has been shown to be enhanced by the binding of the essential trace element copper (Cu++) to form DSF/Cu complexes. We found recently using PDAC cell lines that: i) PCSC increased two days after in vitro fractionated irradiation; ii) DSF/Cu depleted PCSC during the treatment gap, and abolished in vitro sphere formation of irradiated cells; iii) DSF/Cu downregulated Wnt pathway, a key cancer stem cell pathway, in irradiated PDAC cells, and iv) DSF/Cu blocked radiation induced re-expressing mRNA of stemness genes. These findings provide the rationale for our central hypothesis that DSF/Cu depletes pre-existing PCSC and radiation-induced PCSC which results in significant increases in the efficacy of radiation therapy. In Aim1, we will determine that DSF/Cu eliminates both PCSC and iPCSC in vitro and in vivo. In Aim2, we will examine that RT combined with DSF/Cu can effectively eliminate stem- and nonstem- PDAC cells in a neoadjuvant setting using xeno- and syngeneic- pancreatic tumors in mice. In Aim3, we will compare the efficacy of combination of DSF/Cu, RT and 5-Fluorouracil (5-FU), a commonly used radiosensitizer for PDAC vs conventional chemoradiation consisting of RT and 5-FU in a neoadjuvant setting in xeno- and syngeneic- PDAC mouse model systems . At the conclusion of the proposed studies, we will have evaluated DSF/Cu as a cytotoxic agent of pre-existing PSCS/iPSCS and as a blocker of generation of iPCSC, obtained knowledge of the mechanism(s) by which DSF/Cu enhances efficacy of radiation and chemoradiation therapy, and formed the foundation of a novel neoadjuvant therapy for improved efficacy of radiation and chemoradiation by combination with a FDA approved drug DSF and a nutrition supplement Copper gluconate.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xinhui Wang其他文献
Xinhui Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xinhui Wang', 18)}}的其他基金
Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
- 批准号:
10380153 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
- 批准号:
9914094 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
Prevention of post-therapy breast cancer metastasis
预防乳腺癌治疗后转移
- 批准号:
10606639 - 财政年份:2019
- 资助金额:
$ 18.6万 - 项目类别:
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
T细胞可塑性、融合蛋白和基于CAR T细胞的头颈癌免疫疗法
- 批准号:
10455452 - 财政年份:2018
- 资助金额:
$ 18.6万 - 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
- 批准号:
7877983 - 财政年份:2009
- 资助金额:
$ 18.6万 - 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
- 批准号:
7707605 - 财政年份:2009
- 资助金额:
$ 18.6万 - 项目类别:
B7-H3 in prognosis and immunotherapy of pancreatic cancer
B7-H3 在胰腺癌的预后和免疫治疗中的作用
- 批准号:
8719680 - 财政年份:2009
- 资助金额:
$ 18.6万 - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 18.6万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 18.6万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 18.6万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 18.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




